European Commission, InflaRx

InflaRx wins EU approval for Gohibic in Covid-19-induced ARDS
The European Commission (EC) has granted marketing authorisation under exceptional circumstances for InflaRx’s Gohibic (vilobelimab) for the treatment of SARS-CoV-2-induced acute respiratory distress syndrome (ARDS).
InflaRx’s Market Potential Bolstered by EU Approval of Gohibic
H.C. Wainwright analyst Edward White reiterated a Buy rating on InflaRx (IFRX – Research Report) today and set a price target of $8.00.Stay
InflaRx receives European marketing authorization for Gohibicto treat of SARS-CoV-2-induced acute respiratory distress syndrome
InflaRx receives European marketing authorization for Gohibicto treat of SARS-CoV-2-induced acute respiratory distress syndrome: Jena, Germany Friday, January 17, 2025, 11:00 Hrs
InflaRx stock reiterated at Buy at H.C. Wainwright after EU drug approval
H.C. Wainwright reaffirmed its Buy rating and $8.00 price target for InflaRx NV (NASDAQ:IFRX), following the European Commission's approval of the company's treatment for COVID-19 related complications.
InflaRx announces EC grants marketing authorization to Gohibic for ARDS
InflaRx (IFRX) announced that the European Commission has granted marketing authorization under exceptional circumstances for Gohibic for the
InflaRx gets EU okay for Gohibic for COVID-19 respiratory distress
InflaRx (NASDAQ:IFRX) has received EU regulatory approval for its treatment Gohibic for the treatment of COVID-19 patients experiencing acute respiratory distress. The European Commission granted marketing authorization under exceptional circumstances for Gohibic,
InflaRx: Strategic Buy Rating Amidst Regulatory Milestones and Promising Pipeline
Leerink Partners analyst Joseph Schwartz has maintained their bullish stance on IFRX stock, giving a Buy rating yesterday.Stay Ahead of the ...
Hosted on MSN20h
InflaRx Stock Rises 8% on Conditional EC Nod for COVID-19 Drug
InflaRx N.V. IFRX shares gained 7.7% on Wednesday following the European Commission's (EC) approval of marketing ...
Yahoo Finance6d
InflaRx N.V. (IFRX)
JENA, Germany, Jan. 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today ...
Pharmaceutical Technology11d
INF-904 by InflaRx for Chronic Urticaria Or Hives: Likelihood of Approval
INF-904 is under clinical development by InflaRx and currently in Phase I for Chronic Urticaria Or Hives. According to GlobalData, Phase I drugs for Chronic Urticaria Or Hives have an 87% phase ...
CNN1y
InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR.